bluuebunny/crossref_metadata_2025_split huggingface dataset:
814-P: Treatment Satisfaction in People with T2D Switched from Basal Insulin (BI) to Insulin Glargine 300 U/mL (Gla-300) : Patient-Reported Outcomes from ARTEMIS-DM Study
Authors: ALRUBEAAN KHALID , WILMOT EMMA G. , ROBOREL DE CLIMENS AUDE , MABUNAY MARIA AILEEN N. , PILORGET VALERIE , BERTHOU BAPTISTE , FRECHTEL GUSTAVO , SETHI BIPIN 
Published: May 2022

Treatment satisfaction is the key for treatment adherence, to improve long-term outcomes and avoid diabetes complications. However, there is limited data on treatment satisfaction in people with T2D who switch to Gla-300 from other BI in regions outside US and Europe. The current analysis of the 26-week ARTEMIS-DM study presents patient perspective on treatment satisfaction using the Insulin Treatment Satisfaction Questionnaire (ITSQ) , in people with T2D, from Asia, Middle East Africa (MEA) and Latin America (LaTAm) , uncontrolled on BI and who switched to Gla-300. A total of 362/372 (97.3%) participants completed the study. Mean ± SD ITSQ total score increased from baseline 76.30 ± 15.63 to 83.51 ± 13.29 and 84.42 ± 13.15 at Weeks 12 and 26, respectively. Improvements were noted for all ITSQ domain scores, especially glycemic control (baseline: 65.83; mean change from baseline to Week 12: 15.12 and Week 26: 16.06) (Table) . Despite similar mean baseline scores (73.to 79.31) , LS mean change in ITSQ total score was numerically greater in LaTAm (10.86) and MEA (10.40) compared with Asia (1.56) at Week 26. In ARTEMIS-DM study, in people with T2D uncontrolled on BI, switching to Gla-300 demonstrated improvement in treatment satisfaction and specifically in glycemic control in a diverse population from multiple geographic regions.

Disclosure
K.Alrubeaan: Research Support; Sanofi. E.G.Wilmot: Advisory Panel; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Sanofi, Research Support; Insulet Corporation, Novo Nordisk, Speaker's Bureau; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Novo Nordisk, Sanofi. A.Roborel de climens: Employee; IQVIA Inc., Sanofi. M.N.Mabunay: Employee; Sanofi. V.Pilorget: None. B.Berthou: None. G.Frechtel: None. B.Sethi: None.

Funding
Sanofi
815-P: A Nationwide Cross-Sectional Survey of Knowledge and Practices of Diabetes Drug Injection Techniques of Patients, Nurses, and Physicians: The China IT Improve Study
Authors: GUO LIXIN , JI QIUHE , JIANG SHENG , LIU DONGFANG , LIU JING , RAN XINGWU , XUE YAOMING , ZHANG QIU 
Published: May 2022

Introduction: This survey studied the knowledge and/or practices of drug injection techniques of diabetes patients, nurses, and physicians to guide formulating national standardized diabetes drug injection guidelines.
Methods: Patients, nurses, and physicians were recruited from 259 primary, 150 secondary, and 100 tertiary care hospitals chosen using stratified cluster sampling. Their knowledge and/or practices of drug injection techniques were surveyed using the Diabetes Drug Injection Knowledge and Practice Questionnaire for Physicians, Nurses and Patients.
Results: Totally 10694, 2643 and 2816 eligible questionnaires were collected from diabetes patients (92.3% type 2 diabetes) , physicians and nurses, respectively. Needlestick injury occurred in 13.0% patients, 19.8% patients had hypoglycemic episodes and 54.5% patients failed to attain the target HbA1c. Care setting and injection practice were significant determinants of needlestick injury, hypoglycemia and target HbA1c attainment. Overall, 48.9% physicians and 20.4% nurses had a poor knowledge domain score. Care setting, training, and diabetes care experience were significant determinants of diabetes drug injection knowledge domain scores in both physicians and nurses. Furthermore, &gt;92% of the nurses properly performed the steps of injecting diabetes drugs. Needle injury occurred in 24.0% nurses. Care setting, nurse professional levels, and diabetes care experience were significant determinants of needlestick injury.
Conclusions: This nationwide survey offers insights into diabetes drug injection knowledge and practices in China and provides evidence for drafting nationwide guidelines for diabetes drug injection techniques.

Disclosure
L.Guo: None. Q.Ji: None. S.Jiang: None. D.Liu: None. J.Liu: None. X.Ran: None. Y.Xue: None. Q.Zhang: None.
820-P: Testosterone Treatment Improves Glycemic Control and Leads to Remission in 56.8% of Patients with Hypogonadism and Type 2 Diabetes (T2DM) : Update of Real-World Data from a Registry Study
Authors: HAIDER AHMAD , HAIDER KARIM S. , SAAD FARID 
Published: May 2022

Background: Prevalence of hypogonadism is as high as 50% in men with T2DM. ADA Guidelines recommend measuring testosterone in men with T2DM.
Methods: In a registry of 883 men with hypogonadism, 370 men (41.9%) have T2DM. 190 received TU 1000 mg/12 weeks (T-group) , 180 opted against treatment (CTRL) . All patients received standard diabetes care including lifestyle courses at a diabetes center. Remission was defined as discontinuation of diabetes drugs and HbA1c &lt;6.5% for the remaining observation time. Means and standard deviations of absolute measures over 13 years of treatment are reported.
Results: Mean follow-up 9.3±3.2, baseline age: 61.0±5.3 (T-group) and 63.0±4.9 (CTRL) years.
HbA1c decreased from 9.5±1.4% to 5.5±1.2% (79.8±15.5 to 36.6±1.9 mmol/mol) in the T-group and increased from 7.8±0.7% to 10.5±1.2% (61.8±7.7 to 91.7±13.3 mmol/mol) in CTRL (p&lt;0.00for both) .
Fasting glucose (mmol/L) decreased from 7.9±1.3 to 5.4±0.1 in the T-group and increased from 6.4±0.8 to 8.2±1.3 in CTRL (p&lt;0.00for both) .
HOMA-IR decreased from 10.2±2.1 to 1.5±0.3 in the T-group and increased from 7.3±1.3 to 14.8±2.5 in CTRL (p&lt;0.00for both) .
In the T-group, 89 men (46.8%) received insulin at baseline at a mean dose of 38.0±13.3 U/d. Dose requirement declined from 38.0±13.3 to 4.1±5.7 during the observation period. In CTRL, 71 men (39.4%) received insulin at baseline at a mean dose of 31.2±6.1 U/d. Dose requirement increased from 31.2±6.1 to 44.5±5.6 (p&lt;0.00for both) .
In the T-group, 1patients (56.8%) went into remission. The median time to remission was 87 months.
Conclusions: Long-term testosterone therapy with TU in men with hypogonadism and T2DM progressively improved glycemic control. More than half of men achieved remission. Glycemic control deteriorated in untreated men.

Disclosure
A.Haider: Other Relationship; Bayer AG. K.S.Haider: Other Relationship; Bayer AG. F.Saad: Consultant; Bayer AG, Stock/Shareholder; AbbVie Inc., Bayer AG, GlaxoSmithKline plc.

Funding
Bayer AG
833-P: Impact of Hypoglycemia on Insulin Titration and Fasting Plasma Glucose in Basal Insulin–Treated Type 2 Diabetes: A Subanalysis of the SoliMix Trial
Authors: GIORGINO FRANCESCO , ROSENSTOCK JULIO , RITZEL ROBERT , DEYNELI OGUZHAN , ALVAREZ AGUSTINA , SOUHAMI ELISABETH , MELAS-MELT LYDIE , MCCRIMMON RORY J. 
Published: May 2022

Introduction: The SoliMix trial (EudraCT: 2017-003370-13) found better HbA1c with weight benefit and lower hypoglycemia risk for iGlarLixi vs. premix BIAsp 30 in people with type 2 diabetes advancing from basal insulin plus oral antihyperglycemic drugs. This exploratory analysis investigated whether hypoglycemia influenced insulin titration and achievement of fasting plasma glucose (FPG) targets with each therapeutic option.
Methods: Total insulin dose changes from baseline to Week 12 were stratified by hypoglycemia (yes/no) in each treatment arm and ADA Level 2 hypoglycemia (&lt;54 mg/dL [&lt;3.0 mmol/L]) event rates during Weeks 0-12 were modeled according to FPG at Week 12 (when most insulin titration occurred) .
Results: Lesser insulin dose increases occurred in both treatment groups for those who experienced hypoglycemia (mean ± SD iGlarLixi: 3.9 ± 12.5 U; BIAsp 30: 11.0 ± 18.8 U) vs. those who did not (mean ± SD iGlarLixi: 11.2 ± 9.9 U; BIAsp 30: 19.4 ± 19.3 U) . While higher FPG at Week 12 correlated with greater event rates of hypoglycemia in both treatment arms, event rates were higher for BIAsp 30 than for iGlarLixi irrespective of FPG (Figure) .
Conclusions: More frequent hypoglycemia with premix BIAsp 30 than with iGlarLixi may result in lower insulin doses, thus hampering insulin titration and resulting in higher FPG.

Disclosure
F.Giorgino: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Consultant; Lilly Diabetes, Sanofi, Research Support; Lilly Diabetes, Roche Diabetes Care, Takeda Pharmaceutical Company Limited. J.Rosenstock: Consultant; AstraZeneca, Other Relationship; Applied Therapeutics, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Hanmi Pharm. Co., Ltd., Intarcia Therapeutics, Inc., Novo Nordisk, Oramed Pharmaceuticals, Sanofi, Zealand Pharma A/S, Research Support; Genentech, Inc., Merck & Co., Inc., Metacrine, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., vTv Therapeutics. R.Ritzel: Consultant; Novo Nordisk, Sanofi, Speaker's Bureau; AstraZeneca, Lilly, Novartis Pharmaceuticals Corporation, Novo Nordisk, Pfizer Inc., Sanofi. O.Deyneli: Advisory Panel; Abbott Diabetes, AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Novo Nordisk, Roche Diagnostics, Sanofi, Speaker's Bureau; Abbott, AstraZeneca, Berlin-Chemie AG, Bilim Ilaç, Boehringer Ingelheim International GmbH, Medtronic, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk, Roche Diabetes Care, Sanofi. A.Alvarez: Employee; Sanofi. E.Souhami: Employee; Sanofi, Stock/Shareholder; Sanofi. L.Melas-melt: None. R.J.Mccrimmon: Advisory Panel; Novo Nordisk, Sanofi, Research Support; Diabetes UK, European Union, MedImmune.

Funding
Sanofi
838-P: Lipotoxicity-Induced Liver Cell Injury Is Prevented by a Novel Positive Allosteric Modulator of the GABAA Receptor
Authors: ROHBECK ELISABETH , ROMERO ALEJANDRA , KNEBEL BIRGIT , BELGARDT BENGT-FREDERIK , RODEN MICHAEL , ROMACHO TANIA , ECKEL JÜRGEN 
Published: May 2022

NAFLD is a highly prevalent condition currently lacking an approved pharmacological therapy. GABA, besides being a neurotransmitter, has been proposed to protect from liver toxicity in both in vivo an in vitro models. We aimed to determine if a novel positive allosteric modulator (PAM) of the GABAA receptor, the thioacrylamide-derivative HK4 which is devoid of blood brain barrier penetration, can protect human hepatocytes against lipotoxicity-induced injury.
Patch clamping in HEK-293 cells and calcium influx measurements in INS-1E cells proved HK4 as a selective PAM of the GABAA receptor. The expression of several main GABAA receptor subunits (α1, α3, α5, β2/3 and γ2) was demonstrated by Western blotting of HepG2 cells. Next generation sequencing was performed and an effect of HK4 on the gene expression profile in response to palmitate was observed. A preventive effect of HK4 on palmitate-induced apoptosis was demonstrated by reduced caspase 3/7 activity both in HepG2 (47.32 ± 6.92 % vs. 1065 ± 98.68 %) and human primary hepatocytes (57.13 ± 21.47 % vs. 155.1 ± 3.78 %) . This effect was further confirmed by the TUNEL assay (6.41 ± 1.42 % vs. 11.62 ± 0.99 % TUNEL positive cells) . This anti-apoptotic effect was mediated through reduced protein expression of cleaved PARP-1, reduced phosphorylation of NF-κB, and by upregulation of the ER chaperone PDI, as measured by Western blotting.
In conclusion, GABAergic signaling reduces lipotoxic-induced apoptosis in hepatocytes by preventing inflammation, DNA damage and ER stress. Therefore, we propose that HK4 may arise as an innovative pharmacological tool to treat or prevent NASH as a first-in-class drug.

Disclosure
E.Rohbeck: None. A.Romero: None. B.Knebel: None. B.Belgardt: None. M.Roden: Advisory Panel; Eli Lilly and Company, Research Support; Boehringer Ingelheim International GmbH, Nutricia, Speaker's Bureau; Novo Nordisk. T.Romacho: None. J.Eckel: Stock/Shareholder; CureDiab GmbH.

Funding
EFRE-0400192
84-LB: A Personalized Retrospective Continuous Glucose Monitoring (CGM) Report Improves Engagement and Glycemic Control in a Remote Monitoring Diabetes Program (RDMP)
Authors: ELLIS ROBERT J. , KOMPALA TEJASWI , WENG KEVIN , BROOKS ROBERT J. , SALEHI ATOUSA , JAMES ROBERTA , LIU HAU 
Published: May 2022

Introduction: Retrospective review of CGM data is associated with improved glycemic control in people with diabetes, but self-initiated data review is uncommon. The objective of this study was to examine the impact of a novel “CGM-powered Insights Report” on program engagement and glycemic control within Livongo for Diabetes, a RDMP.
Methods: Members enrolled in the RDMP and who authorized data sharing of their existing Dexcom CGM automatically received biweekly Insight Report emails. These Reports provided personalized analysis of CGM trends and suggested next steps within the digital coaching program. The impact of engaging with Insight Reports was assessed via (1) odds ratios and Fisher’s exact tests on the relative recency of key RMDP program feature utilization; and (2) linear regression to quantify its impact on changes in glycemic control.
Results: 1105 members (436 T1D, 464 T2D using insulin, 205 T2D not using insulin) who received their first report by February 1, 2022 were included for analysis. On average, members received 7 Reports and opened 51% of them. Members who opened at least one Report (vs. opened no Reports) were more likely to subsequently utilize the mobile app (OR 1.6) , web portal (OR 1.9) , food logger (OR 1.8) and 1-on-1 coach chat feature (OR 3.2) (all p &lt; .05) . After controlling for demographic and clinical characteristics, baseline glucose metrics, and number of Reports received, members who opened more Reports were more likely to show improvements in mean sensor glucose, Time In Range, and Time Above Range (all p &lt; .05) .
Conclusions: For CGM users within an RDMP, engagement with a personalized Insights Report is associated with increased engagement across other program features, and improvements in glycemic control. Beyond the benefits of CGM itself, surfacing actionable insights within an RDMP adds value by driving members towards increased program engagement, specifically digital coaching.

Disclosure
R. J. Ellis: Employee; Teladoc Health. T. Kompala: Consultant; Eli Lilly and Company, Employee; Teladoc Health. K. Weng: Employee; Teladoc Health. R. J. Brooks: Employee; Teladoc Health, Stock/Shareholder; Dexcom, Inc., Teladoc Health. A. Salehi: Employee; Livongo. R. James: Employee; Livongo, Teladoc Health. H. Liu: Employee; Teladoc Health, Stock/Shareholder; Teladoc Health.
841-P: Scientific Basis for the First-in-Human Trial of “Neo-Islet”–Mediated Functional Cure of T1DM: The Intraperitoneal Administration of “Neo-Islets,” 3-D Organoids of Allogeneic Islet and Mesenchymal Stromal Cells from Rodents, Dogs, and Humans Durably Cures
Authors: WESTENFELDER CHRISTOF , CHOWDHURY SABIHA S. , GOOCH ANNA 
Published: May 2022

Initial reports from Clinical Trials with cell-based interventions for the urgently needed therapy of T1DM show: (1) An open, s.c.-placed encapsulation device containing insulin-producing progenitor cells that require anti-rejection drugs has failed to adequately improve glycemic control. (2) The i.v. administration of stem cell-derived insulin-producing cells, requiring anti-rejection drugs, has shown promising results in 1 or 2 subjects. However, their unknown systemic location and inability to retrieve these cells remain a concern. Our approach harnesses the immune-modulating and -isolating, anti-inflammatory, angiogenic, anti-apoptotic and other trophic actions of Mesenchymal Stromal Cells (MSCs) . First, we demonstrated that allogeneic Neo-islets (NIs) , islet-sized organoids composed of equal numbers of MSCs and culture expanded Islet Cells do, when given i.p., omentally engraft, redifferentiate, re-express all islet hormones (Abstract this meeting) and permanently restore euglycemia in auto-immune diabetic NOD mice, i.e., without encapsulation devices or antirejection drugs. The omentum becomes the new endocrine pancreas. Second, i.p. therapy of spontaneously diabetic pet dogs with allogeneic canine NIs significantly improved glycemia and insulin needs (&gt; 3 years) , and this without immune response. Third, human NIs permanently correct streptozotocin-induced diabetes in NOD/SCID mice. Removal of the omentally-engrafted NIs promptly restores the diabetic state. No long-term complications of the NI therapy have been observed. Based on this body of evidence, a successful Pre-IND meeting with the FDA was held and final Proof-of-Concept studies that are expected to lead IND approval are ongoing.

Disclosure
C.Westenfelder: None. S.S.Chowdhury: Employee; SymbioCellTech, LLC. A.Gooch: Board Member; SymbioCellTech, LLC., Employee; SymbioCellTech, LLC., Stock/Shareholder; SymbioCellTech, LLC.
846-P: Advancing Therapy in Basal Insulin–Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline Age, Diabetes Duration, and Renal Function
Authors: HOME PHILIP , ROSENSTOCK JULIO , GIORGINO FRANCESCO , BLÜHER MATTHIAS , DJABALLAH KHIER , PEGELOW KATRIN , MELAS-MELT LYDIE , MCCRIMMON RORY J. 
Published: May 2022

Introduction: SoliMix (EudraCT: 2017-003370-13) found better HbA1c, weight benefit, and lower hypoglycemia risk with iGlarLixi vs. premix BIAsp 30 in people with type 2 diabetes (T2D) advancing from basal insulin (BI) + oral antihyperglycemic drugs (OADs) .
Methods: Adults with T2D and HbA1c 7.5-10.0 % on BI + 1-2 OADs were randomized to once-daily iGlarLixi or twice-daily BIAsp 30 for 26 weeks. Primary outcomes were non-inferiority in HbA1c change or superiority in body weight change from baseline to Week 26. SoliMix endpoints were assessed here by baseline age (&lt;65, ≥65 years) , T2D duration (&lt;10, ≥years) , and renal function (eGFR ≥90, ≥60-&lt;90, and &lt;60 mL/min/1.73 m2) .
Results: No differences in treatment effect were observed across subgroups for HbA1c or body weight changes (heterogeneity p&gt;0.05; Table) ; both primary objectives were met in the age, T2D duration, and the eGFR ≥60-&lt;90 mL/min/1.73 m2 subgroups. Baseline subgroup had no effect on the lesser insulin dose increments seen in SoliMix with iGlarLixi vs. BIAsp 30 (p&gt;0.80) . The advantage of iGlarLixi over BIAsp 30 for Level 2 hypoglycemia was found in all subgroups with no difference in treatment effect (p&gt;0.10) .
Conclusions: The primary findings for iGlarLixi vs. BIAsp 30 were unaffected by baseline age, T2D duration, or renal function.

Disclosure
P.Home: Advisory Panel; Kriya Therapeutics, Consultant; Mundipharma, Sanofi, Other Relationship; AstraZeneca, Sanofi, Research Support; Gan & Lee Pharmaceuticals, Sanofi, Speaker's Bureau; Gan & Lee Pharmaceuticals, Medscape. J.Rosenstock: Consultant; AstraZeneca, Other Relationship; Applied Therapeutics, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Hanmi Pharm. Co., Ltd., Intarcia Therapeutics, Inc., Novo Nordisk, Oramed Pharmaceuticals, Sanofi, Zealand Pharma A/S, Research Support; Genentech, Inc., Merck & Co., Inc., Metacrine, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., vTv Therapeutics. F.Giorgino: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Consultant; Lilly Diabetes, Sanofi, Research Support; Lilly Diabetes, Roche Diabetes Care, Takeda Pharmaceutical Company Limited. M.Blüher: Consultant; AstraZeneca, Lilly, Novo Nordisk A/S, Pfizer Inc., Sanofi, Speaker's Bureau; Bayer AG, Boehringer Ingelheim International GmbH, Novartis AG. K.Djaballah: Employee; Sanofi. K.Pegelow: Employee; Sanofi-Aventis Deutschland GmbH. L.Melas-melt: None. R.J.Mccrimmon: Advisory Panel; Novo Nordisk, Sanofi, Research Support; Diabetes UK, European Union, MedImmune.

Funding
Sanofi
849-P: Factors Influencing the Selection of Glucose-Lowering Medications among Physicians Treating Patients with Type 2 Diabetes in Real World
Authors: ABUDAHESH JOUD A. , AIJEBREEN JOUD A. , ALHALEES DANAH Z. , ALBRAITHEN GHAIDA , BAMOGADDAM GHADA S. , AL-SOFIANI MOHAMMED 
Published: May 2022

Background: Factors considered when selecting a diabetes medication for patients with type 2 diabetes (T2D) in clinical practice may differ from those recommended by professional societies.
Objective: To identify factors that play a major role in guiding the selection of diabetes medications in the real world.
Method: We asked 135 physicians [67% Generalists (Internists and General Practitioners) and 33% Specialists (Endocrinologists and Diabetologists) ] in Saudi Arabia to select a diabetes medication they frequently prescribe in certain clinical scenarios. Then we asked them to rank a set of factors as (“Major,” “Minor,” or “Not” a consideration) according to the degree those factors would typically influence their selection of a particular medication.
Results: Sulfonylurea is the most frequently prescribed second-line agent. Majority (89%) reported prescribing GLP-1 receptor agonists (GLP-1 RA) to “50% of their patients with T2D and ischemic heart disease; and over 2/3 prescribe SGLT-2 inhibitors (SGLT-2i) to &lt;50% of their patients with T2D and heart failure. Strikingly, 41% and 32% of the Generalists did NOT rank “Renal benefits” with SGLT-2i and “cardiovascular benefits” with GLP-1 RA, respectively, as “major consideration” when prescribing these agents. Medication cost was ranked as a “major consideration” by 75% of Specialists and 65% of Generalists when prescribing GLP-1 RA, and by 57% of Specialists and 71% Generalists when prescribing SGLT-2i.
Conclusion: Despite the recent advances in diabetes therapy, medication cost and inadequate awareness of the cardiovascular and renal benefits of novel diabetes agents, particularly among non-specialists, remain major barriers to the wide adoption of recommendations from professional societies. Policies to improve access to novel diabetes medications and disseminate the awareness about the evidence-based benefits of these medications are needed

Disclosure
J.A.Abudahesh: None. J.A.Aijebreen: None. D.Z.Alhalees: None. G.Albraithen: None. G.S.Bamogaddam: None. M.Al-sofiani: None.
850-P: Greater HbA1c Reduction with iGlarLixi vs. Insulin Glargine and Lixisenatide Regardless of Levels at Screening: Subgroup Analysis of the LixiLan-O Asia Pacific Trial
Authors: HE YIFAN , YANG WENYING , XIAOLIN DONG , YUAN GUOYUE , LIU MING , XIAO JIANZHONG , GU SHENGHONG , CHEN LIJUAN , SOUHAMI ELISABETH 
Published: May 2022

Introduction: LixiLan-O-AP (NCT03798054) showed greater HbA1c improvement with iGlarLixi vs. iGlar or Lixi in Asian Pacific adults with type 2 diabetes (T2D) . This pre-defined analysis assessed iGlarLixi efficacy by HbA1c levels at screening.
Methods: Adults (N=878) with suboptimally controlled T2D (HbA1c of 7.5-% or 7-% depending on background oral antihyperglycemic drug [OAD] use) on metformin ± a second OAD were randomized 2:2:1 to iGlarLixi, iGlar or Lixi for 24 weeks. Three screening HbA1c subgroups were defined: &lt;8, 8-&lt;9, ≥9 %.
Results: At Week 24, in all HbA1c subgroups, iGlarLixi was associated with greater HbA1c reductions vs. iGlar or Lixi and reached mean HbA1c levels &lt;7 %. iGlarLixi also showed greater 2-h postprandial glucose reductions, and a higher proportion of participants reaching HbA1c &lt;7 % and HbA1c &lt;7 % without weight gain, vs. iGlar or Lixi (Table) . Incidence and rates of documented hypoglycemia ≤70 mg/dL (≤3.9 mmol/L) were similar between iGlarLixi and iGlar in the 8-&lt;9 % and ≥9 % subgroups but were slightly higher with iGlarLixi vs. iGlar in the &lt;8 % subgroup.
Conclusions: Regardless of HbA 1c level at screening, iGlarLixi demonstrated better glycemic control vs. iGlar or Lixi, with over 75% of participants achieving the recommended target HbA 1c (&lt;7 %) with iGlarLixi, even those with HbA1c ≥9 % at screening.

Disclosure
Y. He: None. W. Yang: Other Relationship; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Mer, Merck Sharp & Dohme Corp., Novo Nordisk, Sanofi-Aventis Deutschland GmbH, Servier Laboratories. M. Liu: None. J. Xiao: None. S. Gu: Employee; Sanofi China. L. Chen: None. E. Souhami: Employee; Sanofi. Stock/Shareholder; Sanofi.

Funding
Funding: Sanofi